Nucleoside analogues for the treatment of coronavirus infections
- PMID: 31125806
- PMCID: PMC7102703
- DOI: 10.1016/j.coviro.2019.04.002
Nucleoside analogues for the treatment of coronavirus infections
Abstract
Recent outbreaks of SARS-Coronavirus and MERS-Coronavirus (CoV) have heightened awareness about the lack of vaccines or antiviral compounds approved for prevention or treatment of human or potential zoonotic CoVs. Anti-CoV drug development has long been challenged by the activity of a 3' to 5' proofreading exoribonuclease unique to CoVs. Recently, a promising nucleoside analogue with broad-spectrum activity against CoVs has been identified. This review will discuss progress made in the development of antiviral nucleoside and nucleotide analogues targeting viral RNA synthesis as effective therapeutics against CoV infections and propose promising strategies for combination therapy.
Copyright © 2019. Published by Elsevier B.V.
Figures

References
-
- Revised U.S. Surveillance Case Definition for Severe Acute Respiratory Syndrome (SARS) and Update on SARS Cases — United States and Worldwide, December 2003. [date unknown]. - PubMed
-
- WHO | Middle East respiratory syndrome coronavirus (MERS-CoV).WHO [date unknown.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous